Chronic myeloid leukemia treatment with Imatinib: An experience from a private tertiary care hospital

The data presents 75 chronic myeloid leukemia patients diagnosed over a period 6 years i.e. from 2002 to 2008. The most common presentation was splenomegaly and 97% achieved complete hematological response at median duration of 4.3 weeks. The uniqueness of this study is follow-up with molecular resp...

Descripción completa

Detalles Bibliográficos
Autores principales: Doval, D. C., Batra, Ullas, Goyal, Sumit, Sharma, Ajay, Azam, Saud, Shirali, Rashmi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2013
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3902620/
https://www.ncbi.nlm.nih.gov/pubmed/24516305
http://dx.doi.org/10.4103/0971-5851.123725
_version_ 1782301015439048704
author Doval, D. C.
Batra, Ullas
Goyal, Sumit
Sharma, Ajay
Azam, Saud
Shirali, Rashmi
author_facet Doval, D. C.
Batra, Ullas
Goyal, Sumit
Sharma, Ajay
Azam, Saud
Shirali, Rashmi
author_sort Doval, D. C.
collection PubMed
description The data presents 75 chronic myeloid leukemia patients diagnosed over a period 6 years i.e. from 2002 to 2008. The most common presentation was splenomegaly and 97% achieved complete hematological response at median duration of 4.3 weeks. The uniqueness of this study is follow-up with molecular response monitoring. Nearly, 30% patients achieved major molecular response (MMoR) by 12 months. 70% of patients achieved MMoR by median time of 60 months. Only 10% of the patient who achieved MMoR by 18 months had lost their responses subsequently.
format Online
Article
Text
id pubmed-3902620
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Medknow Publications & Media Pvt Ltd
record_format MEDLINE/PubMed
spelling pubmed-39026202014-02-10 Chronic myeloid leukemia treatment with Imatinib: An experience from a private tertiary care hospital Doval, D. C. Batra, Ullas Goyal, Sumit Sharma, Ajay Azam, Saud Shirali, Rashmi Indian J Med Paediatr Oncol Original Article The data presents 75 chronic myeloid leukemia patients diagnosed over a period 6 years i.e. from 2002 to 2008. The most common presentation was splenomegaly and 97% achieved complete hematological response at median duration of 4.3 weeks. The uniqueness of this study is follow-up with molecular response monitoring. Nearly, 30% patients achieved major molecular response (MMoR) by 12 months. 70% of patients achieved MMoR by median time of 60 months. Only 10% of the patient who achieved MMoR by 18 months had lost their responses subsequently. Medknow Publications & Media Pvt Ltd 2013 /pmc/articles/PMC3902620/ /pubmed/24516305 http://dx.doi.org/10.4103/0971-5851.123725 Text en Copyright: © Indian Journal of Medical and Paediatric Oncology http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Doval, D. C.
Batra, Ullas
Goyal, Sumit
Sharma, Ajay
Azam, Saud
Shirali, Rashmi
Chronic myeloid leukemia treatment with Imatinib: An experience from a private tertiary care hospital
title Chronic myeloid leukemia treatment with Imatinib: An experience from a private tertiary care hospital
title_full Chronic myeloid leukemia treatment with Imatinib: An experience from a private tertiary care hospital
title_fullStr Chronic myeloid leukemia treatment with Imatinib: An experience from a private tertiary care hospital
title_full_unstemmed Chronic myeloid leukemia treatment with Imatinib: An experience from a private tertiary care hospital
title_short Chronic myeloid leukemia treatment with Imatinib: An experience from a private tertiary care hospital
title_sort chronic myeloid leukemia treatment with imatinib: an experience from a private tertiary care hospital
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3902620/
https://www.ncbi.nlm.nih.gov/pubmed/24516305
http://dx.doi.org/10.4103/0971-5851.123725
work_keys_str_mv AT dovaldc chronicmyeloidleukemiatreatmentwithimatinibanexperiencefromaprivatetertiarycarehospital
AT batraullas chronicmyeloidleukemiatreatmentwithimatinibanexperiencefromaprivatetertiarycarehospital
AT goyalsumit chronicmyeloidleukemiatreatmentwithimatinibanexperiencefromaprivatetertiarycarehospital
AT sharmaajay chronicmyeloidleukemiatreatmentwithimatinibanexperiencefromaprivatetertiarycarehospital
AT azamsaud chronicmyeloidleukemiatreatmentwithimatinibanexperiencefromaprivatetertiarycarehospital
AT shiralirashmi chronicmyeloidleukemiatreatmentwithimatinibanexperiencefromaprivatetertiarycarehospital

Ejemplares similares